Revenue jumped 21.9% but Horticulture margin halved and NPAT fell 8%

What changed

Revenue rose 21.9% to $309.3m, but earnings leverage was thin: EBITDA grew only 3.6% to $56.4m, PBT rose 5.0% to $45.3m, and reported NPAT fell 8.0% to $26.1m. Underneath that, segment mix shifted decisively. Horticulture revenue dropped to $117.3m (37.9% of group, from 50.2%) and its segment result more than halved from $29.4m to $15.2m, taking margin from ~23.0% to ~13.0%. Global Proteins is now the largest division at $151.7m revenue and $30.0m result (~19.8% margin). The prior Food Ingredients and Other lines no longer appear as separate segments, signalling a reporting re-cut. Operating cash outflow narrowed to -$30.6m from -$35.3m, and gross borrowings fell $13.8m to $39.4m, taking net debt to roughly $3.2m (0.06x EBITDA) from $22.3m (0.41x) a year earlier.

What matters

• Horticulture earnings deterioration. A ~$14.2m fall in segment result on a ~$10.0m revenue decline is the dominant driver of the group's weak operating leverage. Without improvement here, group EBITDA growth will continue to lag top-line growth.
• Mix rotation to Global Proteins. Growth in Global Proteins is now doing the heavy lifting, and its ~19.8% margin is higher than Horticulture's current ~13.0%. The question is whether that is structural or cyclical pricing.
• Balance sheet strength. Net debt is effectively negligible at $3.2m against $56.4m EBITDA. This gives Scales significant optionality for capital allocation, but also raises the hurdle for leaving cash idle given ROE weakened from 7.3% to 6.7%.

Expectations

No quantitative forward guidance or stated targets were disclosed in the supplied release. Seasonality context is mixed: in FY21, the first half contained 49.3% of revenue but 76.1% of EBITDA and 105.2% of NPAT, meaning the second half was effectively breakeven at the bottom line. Annualising HY22 revenue naively gives $618.6m versus FY21's $514.6m, a much stronger top-line run rate, but the FY21 seasonality pattern suggests the second half will not meaningfully add to full-year EBITDA unless it diverges from prior shape. The release supports a stronger revenue FY22 but does not support earnings recovery absent a Horticulture margin rebuild.

Quality of result

The PBT result is the cleaner operating read, at +5.0%. The NPAT decline of 8.0% is not explained by tax (effective rate actually fell from 24.4% to 22.6%), and the release references a "reported NPAT" of $35.1m that does not reconcile to the $26.1m statutory line extracted — the supplied disclosure does not bridge underlying to statutory. Cash conversion improved at the margin (OCF/EBITDA -54.2% vs -64.7%), but remained seasonally negative, and pre-lease free cash flow was -$35.8m. The period-end cash increase is therefore not operating-cash-driven but reflects investing inflows and FX. Inventory built 18.5% to $38.7m, broadly tracking revenue growth, so working capital is not flattering the result. Overall, the quality of the earnings print is mediocre: revenue is durable at the run-rate level, but the margin story depends heavily on Horticulture stabilising.

Unresolved

• How the $35.1m "reported NPAT" headline reconciles to the $26.1m statutory line — no bridge was provided.
• Whether Food Ingredients has been absorbed into Global Proteins or otherwise re-cut, and what comparable segment growth looks like on a like-for-like basis.
• Drivers of the Horticulture margin collapse (volume, pricing, cost inflation, FX) and whether these are one-off or persistent.
• The full-period dividend; only the announcement is flagged in extracted text without a declared amount or payout ratio.
• Customer concentration and FX hedge positions, given the FX line was material in cash flows.

This briefing cannot assess whether the Horticulture margin deterioration is cyclical or structural, nor the sustainability of Global Proteins pricing, because neither driver detail nor forward guidance was disclosed in the supplied extraction.

Key metrics

Segment breakdown

Analytical metrics

This analysis was generated using Annolyse, an AI-powered tool that analyses NZX company announcements. The analysis is based on available company filings and standard Annolyse calculations. This is general information only and does not constitute financial advice. The analysis may contain errors. Always read the original company filings and consult a licensed financial adviser before making investment decisions.